m+Medelevator.RU
← Поиск публикаций
Critical reviews in oncology/hematology · 2026

Barrier-matched, pharmacodynamic (PD)-gated immunotherapy development in MSS/pMMR colorectal cancer.

СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Shan Chanchan, Zhang Jian, Zhang Liyuan

Аннотация

Immune checkpoint inhibitors (ICIs) have transformed treatment for deficient mismatch repair/high microsatellite instability (dMMR/MSI-H) colorectal cancer (CRC), but durable benefit remains uncommon in microsatellite-stable/proficient mismatch repair (MSS/pMMR) disease. Negative combination trials may reflect heterogeneous resistance programs tested without adequate biological stratification or prospective pharmacodynamic verification. This narrative and critical Review examines MSS/pMMR CRC through tissue-level immune-desert, immune-excluded, and immune-suppressed contexts, with active liver metastasis treated as a putative organ-context modifier rather than a validated predictive phenotype. We develop a hypothesis-generating, barrier-matched, pharmacodynamic (PD)-gated approach for future trials, not routine care. The workflow separates Tier 1 core stratification-liver-metastasis status, disease burden, core genomics, and baseline plasma circulating tumor DNA (ctDNA)-from Tier 2 tissue-based immune-spatial assessment required for mechanism-matched allocation to most non-hepatic barriers. Therapeutic modules are aligned with the dominant resistance context and reassessed after short induction using prespecified GO/ADAPT/STOP rules. For spatial or tissue-based mechanisms, GO requires a barrier-specific readout when tissue assessment is feasible; ctDNA is a complementary systemic-response signal and cannot by itself establish barrier engagement. Mixed or lesion-discordant phenotypes and inadequate tissue remain exploratory unless a prespecified dominance rule is met. A prototype master protocol would combine mechanism-defined cohorts, contemporaneous controls where feasible, early barrier-specific PD conversion as the primary biological endpoint, 6-month progression-free survival as the primary clinical endpoint, and prespecified expansion, futility, safety, and adaptation rules. Prospective validation is needed before this approach can inform practice.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты